Umbilical cord serum therapy in acute ocular chemical burns

Evaluation of umbilical cord serum therapy in acute ocular chemical burns: a prospective, double-blind, randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN08131903

Enrollment

Registered

2010-07-05

Start date

2005-09-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute chemical ocular burns Injury, Occupational Diseases, Poisoning Burn and corrosion confined to eye and adnexa

Interventions

1. Patients were started on standard medical therapy consisting of: 1.1. Topical ofloxacin hydrochloride 0.3% 6-hourly 1.2. Topical prednisolone acetate 1% 2-hourly 1.3. Topical homatropine 2% three t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with acute ocular chemical burns (grade III, IV and V according to Dua classification) presenting within three weeks of injury 2. Either sex, aged 16 - 50 years

Exclusion criteria

Exclusion criteria: 1. Patients with grade I, II and VI injury 2. Impending perforation

Design outcomes

Primary

Measure	Time frame
Patients were followed up on day 1, day 3, day 7, day 14, day 21 and at the end of 1 month, 2 months and 3 months. Total duration of follow up in all three groups was 3 months. Parameters assessed were at each follow-up included: 1. Pain score 2. Best corrected visual acuity 3. Limbal ischaemia 4. Epithelial defect 5. Corneal clarity and vascularisation 6. Tear film status (Schirmer, TBUT) 7. Intraocular pressure (IOP) 8. Symblepharon formation	—

Measure

Time frame

Patients were followed up on day 1, day 3, day 7, day 14, day 21 and at the end of 1 month, 2 months and 3 months. Total duration of follow up in all three groups was 3 months. Parameters assessed were at each follow-up included: 1. Pain score 2. Best corrected visual acuity 3. Limbal ischaemia 4. Epithelial defect 5. Corneal clarity and vascularisation 6. Tear film status (Schirmer, TBUT) 7. Intraocular pressure (IOP) 8. Symblepharon formation

—

Secondary

Measure	Time frame
Complications arising from injury and/or treatment	—

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 29, 2026